Login to Your Account



SuperGen Starts Rolling NDA For Pancreatic Cancer Therapy

By Randall Osborne


Tuesday, December 31, 2002
Coming in a few days under the wire, SuperGen Inc. said it has begun the rolling submission of a new drug application for Orathecin (rubitecan), an oral chemotherapy drug for refractory pancreatic cancer patients. (Bioworld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription